Drugs / IPN01194
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06305247 | Apr 2024 → Mar 2028 expected | colorectal cancer, head and neck squamous cell carcinoma, melanoma, pancreatic ductal adenocarcinoma | Ipsen | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN01194 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305247 ↗ |
| Action | Inhibit | “ERK1/2 Inhibitor IPN01194” NCT06305247 ↗ |
| Route | Oral | “IPN01194 will be taken orally” NCT06305247 ↗ |